Nitroimidazole adducts as markers for tissue hypoxia: mechanistic studies in aerobic normal tissues and tumour cells
Open Access
- 1 December 1992
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 66 (6) , 1103-1108
- https://doi.org/10.1038/bjc.1992.418
Abstract
Two aspects of the aerobic metabolism of nitroimidazole markers for hypoxia were investigated. Several normal murine tissues which are likely to be well oxygenated bind misonidazole at rates comparable to those of hypoxic regions in tumours. The possibility that this aerobic activation occurs via an oxygen independent process such as an initial two electron reduction was studied. Binding to the oesophageal mucosa of mice which occurred under hypoxia in vitro was inhibited by at least 95% in the presence of 10% oxygen. Dicoumarol, an inhibitor of DT-diaphorase, was shown to cause only small reductions in misonidazole binding to oesophageal epithelium and smooth muscle in vitro and to EMT6 tumours, liver, oesophageal and tracheal epithelium, parotid gland and smooth muscle in vivo. Thus an oxygen-insensitive process is not a major cause of the high binding rate in oesophageal mucosa, and may not contribute significantly to the observed binding in other normal tissues. It has been suggested that metabolism of nitroimidazoles by aerobic cells in tumours might be sufficient to minimise access of these compounds to hypoxic regions, particularly at the micromolar concentrations currently in use clinically. The uptake of 125I-iodoazomycin arabinoside by RIF-1 and EMT6 tumours was found to be directly proportional to injected dose over concentrations between 0.5 and 50 microM. Labelling of hypoxic regions in EMT6 tumours by high specific activity 3H-misonidazole at 1 microM was found to be similar to that obtained at 50 microM.Keywords
This publication has 35 references indexed in Scilit:
- The potentiation of radiation damage by nicotinamide in the SCCVII tumour in vivoRadiotherapy and Oncology, 1990
- Tissue distribution of 14C- and 3H-labelled misonidazole in the tumor-bearing mouseInternational Journal of Radiation Oncology*Biology*Physics, 1990
- DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs?British Journal of Cancer, 1989
- The effect of hypobaric hypoxia on misonidazole binding in normal and tumour-bearing miceBritish Journal of Cancer, 1989
- Microscopic distribution of misonidazole in mouse tissuesBritish Journal of Cancer, 1989
- OXYGEN DEPENDENCE OF BINDING OF MISONIDAZOLE TO RODENT AND HUMAN-TUMORS INVITRO1987
- A novel technique for measuring human tissue pO2 at the cellular levelBritish Journal of Cancer, 1986
- Covalent binding of a fluorinated 2-nitroimidazole to emt-6 tumors in Balb/C mice: detection by f-19 nuclear magnetic resonance at 2.35 TInternational Journal of Radiation Oncology*Biology*Physics, 1986
- Distribution and tumor penetration properties of a radiosensitizer 2-[14C] misonidazole (Ro 07-0582), in mice and rats as studied by whole-body autoradiographyCancer Chemotherapy and Pharmacology, 1986
- Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508International Journal of Radiation Oncology*Biology*Physics, 1984